First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium Self-collection option available at no extra charge at any of Quest's 2,000 patient service centers with a physician's order or through Quest's consumer-initiated test platform at questhealth.com SECAUCUS, N.J., Oct. 15, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnosti ...

The medical laboratory testing industry is growing at a 1-3% compound annual growth rate and is dominated by two publicly traded companies. Quest Diagnostics (NYSE: DGX ) is the stronger of the two companies and is actively I am an individual investor with over two decades of investing experience. I am passionate about finding great value buys and pursuing dividend growth investing, from domestic to international companies. I invest in businesses, not stocks!I cover all aspects of value investing, dividend ...

Quest Diagnostics (DGX) is set to release its third-quarter 2024 results on Oct. 22, before the opening bell. The medical diagnostic testing provider posted adjusted earnings per share (EPS) of $2.35 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 1.73%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 3.31%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. DGX's Q3 Estimates For the third quarter of ...

Goal to broaden access to cost-effective and innovative laboratory services in Ohio SECAUCUS, N.J., Oct. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of select laboratory assets from OhioHealth, a nationally recognized not-for-profit, charitable, integrated health system. Financial terms of the transaction were not disclosed. The goal of the transaction is to broaden access to c ...

Quest Diagnostics Inc. (DGX) continues the strong momentum in its expanding portfolio of Advanced Services, which is poised to help it grow in the upcoming quarters. The company strategically deploys AI and automation to improve its operational quality and efficiency, while Invigorate aims to reach its annual target. Its base business volume remains robust, which is highly encouraging. However, the mounting debt burden on its balance sheet and industry headwinds could pose challenges for Quest Diagnostics' ...

SECAUCUS, N.J., Sept. 25, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial results on Tuesday, October 22, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode ...

Core Viewpoint - Quest Diagnostics (DGX) is experiencing growth driven by strong customer relationships, new client acquisitions, broad health plan access, and advanced diagnostics offerings, currently holding a Zacks Rank 2 (Buy) [1] Factors Driving DGX Stock - The company has seen robust volume growth in its core business, with base clinical volumes increasing by 3.2% in Q2 2024, attributed to new physician and hospital customers and a favorable test mix [2] - Physician Lab Services reported strong growth due to market expansion and new customer acquisitions, alongside significant volume and revenue growth from Medicare Advantage plans [3] Advanced Diagnostics Services - Quest Diagnostics' Advanced Diagnostics services, including molecular genomics and oncology tests, have shown strong growth, particularly in brain health, women's health, and advanced cardiometabolic health in Q2 2024 [4] - The Alzheimer's disease portfolio, including AD-Detect blood testing and cerebrospinal fluid tests, is a key growth driver, with plans to expand the biomarker offerings [5] Financial Performance - The stock has appreciated by 18.8% over the past six months, outperforming the industry average of 11.9%, with expectations for continued upward movement due to core business expansion strategies [7] Challenges Faced - The transition away from COVID-19 testing has led to a significant revenue decline of nearly 85% in 2023, with a projected $175 million decrease in COVID-19 revenues for 2024 [8] - Concerns regarding solvency are present, with long-term debt at $3.82 billion and cash reserves of only $271 million, leading to a declining times interest ratio of 7.7% [9]

Quest Diagnostics (DGX) and Sentara Health Plans announced a multi-year strategic collaboration to expand access to high-quality, affordable and comprehensive laboratory testing for the members of Sentara Health Plans. Per the deal, starting Jan. 1, 2025, DGX will be the exclusive independent national laboratory provider of clinical laboratory and anatomic pathology services for Sentara Health Plans' members, including commercial and government programs. The agreement applies to Sentara Health Plans' member ...

Core Insights - Quest Diagnostics has been named the exclusive independent laboratory provider for all Sentara Health Plans in Virginia and Florida, starting January 1, 2025, which aims to enhance access to laboratory testing for members [1][2]. Group 1: Strategic Collaboration - The multiyear strategic collaboration between Quest Diagnostics and Sentara Health Plans is designed to provide high-quality, affordable laboratory testing services [1][4]. - Quest will expand its patient service center network in collaboration with Sentara to improve patient access in certain regions [3]. Group 2: Goals and Benefits - The partnership aims to reduce healthcare costs while improving access, innovation, and quality of care for Sentara Health Plans members [4]. - Sentara Health Plans serves over 1 million members in Virginia and Florida, indicating a significant market presence for Quest Diagnostics [6]. Group 3: Company Background - Sentara Health is a large not-for-profit healthcare delivery system with over 30,000 employees and 12 hospitals, recognized for clinical quality and safety [5]. - Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the U.S., highlighting its extensive reach in the healthcare ecosystem [7].

Company Overview - Quest Diagnostics (DGX) has acquired select laboratory assets from Allina Health, aligning with its strategy for expansion through acquisitions [1][5] - The acquisition is expected to enhance Quest Diagnostics' laboratory services in Minneapolis and throughout Minnesota and western Wisconsin [1] Financial Impact - Following the acquisition announcement, DGX shares increased by approximately 1.3%, closing at $156.36 [2] - DGX currently has a market capitalization of $17.41 billion and an earnings yield of 5.76%, significantly higher than the industry average of 3.39% [3] Strategic Implications - The acquisition is strategically aligned with DGX's goals, focusing on providing quality, innovative, and affordable laboratory services to various communities [5] - This initiative is part of a broader strategy to generate growth through accretive laboratory acquisitions [5][7] Industry Context - The global clinical laboratory services market was valued at $233.2 billion in 2023, with a projected CAGR of 3.5% by 2030, driven by the increasing burden of chronic diseases and demand for early diagnostic tests [6] - The deal is expected to support Quest Diagnostics' continuous growth strategy through gradual laboratory acquisitions [7] Recent Acquisitions - In August, DGX completed the acquisition of LifeLabs for approximately $1 billion, aimed at enhancing access to diagnostic innovation in North America [9] - DGX also signed an agreement to acquire select assets from University Hospitals' outreach laboratory services, broadening its access in Ohio [10]